The Pharmaceuticals Export Promotion Council of India (Pharmexcil), operating under the auspices of the Ministry of Commerce and Industry, Government of India, has commenced the voter registration process for the 2024-26 Committee of Administration (CoA) elections. This initiative signifies a pivotal phase in shaping the leadership that will steer the future of India’s pharmaceutical export sector.
The registration window is now open, with the deadline set for November 30, 2024. The election will facilitate the selection of representatives ready to tackle industry hurdles, enhance export possibilities, and boost global competitiveness within the pharmaceutical domain.
Voting eligibility follows Pharmexcil’s standard bye-laws, which include:
Ordinary members must adhere to specific export turnover benchmarks calculated from the preceding two fiscal years: \- Micro enterprises need Rs. 25 lakhs (average exports), \- Small enterprises require Rs. 50 lakhs (average exports), \- Medium enterprises necessitate Rs. 1 crore (average exports), \- Non-MSMEs must exceed Rs. 1 crore (average exports).
For associate members, a consistent membership span of three years is mandatory.
Additionally, achieving an average export turnover of Rs. 25 lakhs across the past three financial years is essential. All members must renew their membership for the 2023-24 fiscal year as a general prerequisite.
Eligible members are urged to finalize their registration promptly by presenting the requisite paperwork to Pharmexcil. This due diligence is crucial for those keen on casting their votes and contributing toward electing a capable leadership to adeptly confront the pharmaceutical sector’s dynamic environment.
The Committee of Administration elections transcend mere formal procedure, offering members a unique chance to shape the Council’s strategic direction and priorities. By participating in the vote, members actively engage in driving the sector to surmount global challenges, explore new markets, and fortify India’s stature as a preeminent pharmaceutical leader.